• Clinical Trials - Hepatocellular Cancer

    Study Objective Contact
    A Phase 3, Randomized, Double-Blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib [LCID Study Number: 2013-064] There are no approved therapies for second line treatment of HCC. The purpose of this study is to see if Cabozantinib (XL184) will help patients whose disease worsened after prior treatment with Sorafenib. Patients will receive either study drug or placebo. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma(HCC) [LCID Study Number: 2012-052] The purpose of this study is to see if sorafenib is a safe and effective treatment option for preventing Hepatocellular Cancer (HCC) from returning in “high risk” patients after transplantation. Principal Investigator(s):
    Elizabeth A. Pomfret, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco.
    A Prospective, Multicenter Comparison Of Multiphase Contrast -Enhanced CT And Multiphase Contrast-Enhanced MRI For Diagnosis Of Hepatocellular Carcinoma And Liver Transplant Allocation [LCID Study Number: 2010-064] A Prospective, Multicenter Comparison Of Multiphase Contrast -Enhanced CT And Multiphase Contrast-Enhanced MRI For Diagnosis Of Hepatocellular Carcinoma And Liver Transplant Allocation Principal Investigator(s):
    Sebastian Flacke, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Agnes P. Trabucco,
    Nanette Matrullo.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    Phase 1b/2 Study of Oprozomib in Combination with Sorafenib in Subjects with Advanced Hepatocellular Carcinoma [LCID Study Number: 2014-047] The purpose of this study is to find the maximum tolerable dose of an investigational new drug called oprozomib, in combination with sorafenib in patients with advanced hepatocellular carcinoma. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.